Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone
Experimental Dermatology · 2024-12 · 33 (12)
DOI: 10.1111/exd.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, online erschienen am 23.12.2024. Verfasst von Elena Calama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Almirall R+D Centre, Almirall S.A, Sant Feliu de Llobregat, Spain. Hauptthemen laut MEDLINE: Oxazolone, Dermatitis, Atopic, Disease Models, Animal, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Almirall.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. The aim of this study was to comprehensively characterise a murine model of dermatitis and assess the similarity with the human disease, as well as to profile clinically relevant AD therapies. Four repeated topical administrations of oxazolone in the auricular skin of sensitised mice induced morphological features compatible with AD, including redness and swelling, as well as histological changes typical of spongiotic (eczematous) dermatitis and increased plasmatic IgE. Additionally, key driver Type 2 cytokines involved in the pathophysiology of the disease, IL‐4, IL‐13 and IL − 31, were upregulated in the skin, along with cytokines related to Type 1, 17 and 22 responses, which have been reported to be relevant in the chronic stages of the disease. RNA‐seq studies in OXA model mice samples validate expression changes obtained by q‐PCR and suggest a greater significant similarity with the transcriptomic signature of human AD with respect to psoriasis studies. Oral (cyclosporine, prednisolone and baricitinib) and topical treatments (betamethasone, tacrolimus and crisaborole) were effective inhibiting the induced pathology, as well as modulating the cytokine gene signature of AD. In conclusion, our 4 oxazolone challenges model recapitulates many of the key features of the disease and is responsive to AD standard of care therapies in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Almirall R+D Centre, Almirall S.A, Sant Feliu de Llobregat, Spain.
ORCID-Profile: Elena Calama, Ana I Blanco, Juan L Trincado, Arsenio Nueda, Félix Gil, Gloria Aniorte, Nuria Godessart, Amadeu Gavaldà
Förderung
- Almirall
Zitieren
APA
Calama, E., Blanco, A. I., Trincado, J. L., Nueda, A., Gil, F., Aniorte, G., Godessart, N., & Gavaldà, A. (2024). Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone. Experimental Dermatology, 33(12). https://doi.org/10.1111/exd.70024
Vancouver
Calama E, Blanco AI, Trincado JL, Nueda A, Gil F, Aniorte G, et al. Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone. Experimental Dermatology. 2024;33(12). doi:10.1111/exd.70024
BibTeX
@article{Calama2024,
author = {Calama, Elena and Blanco, Ana I and Trincado, Juan L and Nueda, Arsenio and Gil, Félix and Aniorte, Gloria and Godessart, Nuria and Gavaldà, Amadeu},
title = {Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone},
journal = {Experimental Dermatology},
year = {2024},
volume = {33},
number = {12},
doi = {10.1111/exd.70024}
}
EUVIMED